Journal profile · IMMUNOLOGY
ImmunoTargets and Therapy
ISSN 2253-1556 · Dove Medical Press · United Kingdom
ImmunoTargets and Therapy: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.3 (journal website); JCR Q2 (journal website); fully open access; APC about USD 4,320; median 107 days to acceptance (106 articles, last 24 months); acceptance rate 19% (journal website); 89 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
ImmunoTargets and Therapy is published by Dove Medical Press and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses and CAR-T cell therapy research, together about 37.6% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Professor Michael R Shurin ImmunoTargets and Therapy is an international journal that aims to present and publish basic and clinical research on the aspects of immunology in health and disease. ImmunoTargets and Therapy is primarily focused on the immunological basis of disease and explores the evidence behind new and existing immunotherapies in terms of improving outcomes and, importantly, will seek to define their usage in terms of ultimate uptake and acceptance by the patient and health care professional. ImmunoTargets and Therapy will no longer consider meta-analyses or Mendelian Randomization studies for publication. Case reports/series submitted to ImmunoTargets and Therapy will be diverted to the Case Reports section of the International Medical Case Reports Journal (Journal metric data for this journal can be accessed here). Specific Topics covered in this journal include: Biology and pathophysiology of the immune system in health and disease Immunological basis and immunological markers of diseases Potential targets for immune based therapy including therapeutic and prophylactic vaccines Novel and improved targets for immunodiagnostics and immunomonitoring Treatment protocols to improve management of patient with immune-mediated diseases Impact of management programs and new therapeutic agents Protocols on patient perspectives such as quality of life, adherence, and satisfaction Studies based on in-vitro research need to be supported by comprehensive experimental validation of results. Updated 11 February 2026
From the journal's Aims & Scope
Research area (LetPub): IMMUNOLOGY
Editor-in-chief Michael R ShurinPublisher website
Editorial board by country: 2 in mainland China (about 7%); most named United States 10, India 4, Mainland China 2, Germany 2, Spain 2 (29 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine15.9%
- Immunotherapy and Immune ResponsesImmunology and Microbiology11.7%
- CAR-T cell therapy researchMedicine10%
- Immune Cell Function and InteractionImmunology and Microbiology9.4%
- Immune cells in cancerImmunology and Microbiology5.2%
- Ferroptosis and cancer prognosisMedicine4.2%
- Monoclonal and Polyclonal Antibodies ResearchMedicine4%
- T-cell and B-cell ImmunologyImmunology and Microbiology2.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
SJR, CiteScore, Impact FactorPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 6.3Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.7Publisher website ·
- CiteScore 2026-06
- 3.7LetPub ·
- CiteScore (publisher) 2025
- 1.03Publisher website ·
- SJR 2026-06
- 1.11LetPub ·
- SNIP 2026-06
- 1.03LetPub ·
- h-index
- 48OpenAlex ·
- i10-index
- 155OpenAlex ·
- 2-year mean citedness
- 5.63OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 99.37%LetPub ·
Volume
- Articles per year
- 90LetPub ·
- Downloads per year (publisher)
- 40,125Publisher website ·
Articles by year OpenAlex count · 369 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 68 | 68 | 23 |
| 2025 | 89 | 89 | 689 |
| 2024 | 56 | 56 | 488 |
| 2023 | 14 | 14 | 205 |
| 2022 | 6 | 6 | 167 |
| 2021 | 31 | 31 | 1,468 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
107 daysMedian, submission to acceptance · P25–P75 89 days – 127 days
- Acceptance to online
- median 16 days (106 articles)
- Submission to online
- median 128 days
- Sample
- 106 articles with submission and acceptance dates (179 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 19%Publisher website ·
- Desk decision
- 48 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,320 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,320 | — | — | |
| LetPub | USD 3,300 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics, Peer review, Plagiarism
- Publication ethics
COPE member Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·- Peer review
Accelerated Publication Model summary
This journal offers Accelerated Publication.
Source ↗Publisher website ·- Plagiarism
All submitted manuscripts are checked for plagiarism using Crossref Similarity Check (powered by iThenticate). Model summary
Please be aware that Dove Medical Press checks ALL submitted manuscripts for plagiarism. We use Crossref Similarity Check (powered by iThenticate).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2253-1556
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about ImmunoTargets and Therapy
What CAS zone is ImmunoTargets and Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, ImmunoTargets and Therapy is in Zone 2 of Medicine, and in Zone 2 of the minor category Immunology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of ImmunoTargets and Therapy?
The journal's website gives an impact factor of 6.3 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 3.7, h-index 48.
How long does peer review take at ImmunoTargets and Therapy?
Based on the dates recorded on 106 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 107 days (interquartile range 89–127 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 19%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is ImmunoTargets and Therapy in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 2 of Medicine.
Where are the editorial board members of ImmunoTargets and Therapy based?
Of the 29 board members whose country the journal's board page names, 2 (about 7%) are in mainland China; the countries named most often are United States (10), India (4) and Mainland China (2). Counted from the institutions listed on the board page; for reference only.
Which databases index ImmunoTargets and Therapy?
According to LetPub and DOAJ records, ImmunoTargets and Therapy is indexed in ESCI, Scopus and DOAJ.
Is ImmunoTargets and Therapy open access, and what is the APC?
ImmunoTargets and Therapy is a fully open-access journal. APC about USD 4,320.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .